Compare Bristol-Myers Squibb Co (BMY) vs Core Scientific Inc (CORZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Core Scientific Inc — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Core Scientific Inc trades at $21.91 (market cap $7.02B). The key difference: Bristol-Myers Squibb Co is far larger — about 16.6× Core Scientific Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals.
| BMY | CORZ | |
|---|---|---|
Market Cap | $116.30B | $7.02B |
Sector | Health | Technology |
52-Week High | $62.37 | $29.16 |
52-Week Low | $42.60 | $12.65 |
Enterprise Value | $152.24B | $8.07B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Core Scientific (CORZ) trades at $22.71, down 3.32% today, with a bearish technical signal despite strong analyst support. The company is transitioning from Bitcoin mining to AI colocation, with Q1 2026 colocation revenue surging to $77.5M and gross margins of 57%. However, the company continues to report significant losses with a net income margin of -341.68% and negative cash flow of $525.6M in 2025.
The outlook remains speculative with substantial execution risk despite analyst optimism. While the AI pivot offers growth potential, persistent losses and cash burn present significant challenges. The consensus price target of $34.17 suggests 50% upside potential, but investors must weigh the high-risk transformation against the company's current financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →
